Overview

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Status:
Active, not recruiting

Trial end date:
2022-01-18

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Zanubrutinib